C-71980262, A novel small molecule against human papilloma virus-16 E6 (HPV-16 E6) with anticancer potency against cervical cancer: A computational guided in vitro approach

Document Type : Original Article

Author

Department of Microbiology & Clinical Parasitology, College of Medicine, King Khalid University, Abha, Saudi Arabia

Abstract

Objective(s): Human papillomavirus-16 E6 (HPV-16 E6) forms a heterodimer complex to up-regulate the degradation of tumor suppressor protein p53 to promote cervical cancer. This study aims to identify a novel small molecule against E6 with anticancer efficacy against HPV-16, a prime high-risk serotype inducer for cervical cancer.
Materials and Methods: Autodock-vina-based high-throughput virtual screening and atomistic molecular dynamic simulations were used for identification of targeted lead molecules. HPV-16 infected SiHa and CaSki cell lines were used to validate the lead compound in vitro. Proliferation of cancer cells was analyzed by MTT assay and flow cytometry was used to analyze target inhibition, apoptosis, and p53.  
Results: High throughput virtual screening and molecular dynamic simulation identified C-71980262 as a lead candidate that could bind HPV-E6. Atomistic molecular dynamic simulation of E6 bound C-71980262 for 200 ns showed that the predicted ligand binding was stable with minimal energy expenditure, proposing the viability and veracity of the assessed molecule. C-71980262 inhibited the proliferation of SiHa and CaSki cells with GI50 values of 355.70 nM and 505.90 nM, respectively. The compound reduced HPV-16 E6 while inducing early and late-phase apoptosis in these cells. Treatment with C-71980262 increased the p53-positive populations in SiHa and CaSki cells.  
Conclusion: C-71980262 was identified as a novel lead molecule that could inhibit the HPV-16 E6 and increase p53 in cervical cancer cells. Further in vitro and in vivo validation is warranted to consolidate and corroborate this lead compound against HPV-induced cancer progression. 

Keywords

Main Subjects

References

1. Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med 2020; 17: 864-878.
2. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009; 384: 260-265.
3. Rautava J, Syrjänen S. Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol 2012; 6: S3-15.
4. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health 2020; 8: 552028-552046.
5. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16: 1-17.
6. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-79.
7. Moeinzadeh M, Kheirkhah B, Amini K, Pouryasin A. Classification and identification of human papillomavirus based on its prevalence and development of cervical lesion among Iranian women. Bioimpacts 2020; 10: 235-242.
8. Burd EM. Human papillomavirus laboratory testing: The changing paradigm. Clin Microbiol Rev 2016; 29: 291-319.
9. Yu L, Majerciak V, Zheng ZM. HPV16 and HPV18 genome structure, expression, and post-transcriptional regulation. Int J Mol Sci 2022; 23: 4943-4972.
10. Della Fera AN, Warburton A, Coursey TL, Khurana S, McBride AA. Persistent human papillomavirus infection. Viruses 2021; 13: 321-336.
11. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. Embo J 1989; 8: 3905-3910.
12. Schütze DM, Krijgsman O, Snijders PJ, Ylstra B, Weischenfeldt J, Mardin BR, et al. Immortalization capacity of HPV types is inversely related to chromosomal instability. Oncotarget 2016; 7: 37608-37621.
13. Wayengera M. Zinc finger arrays binding human papillomavirus types 16 and 18 genomic DNA: Precursors of gene-therapeutics for in-situ reversal of associated cervical neoplasia. Theor Biol Med Model 2012; 9: 30-42.
14. Zanier K, Stutz C, Kintscher S, Reinz E, Sehr P, Bulkescher J, et al. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6. PLoS One 2014; 9: e112514-112525.
15. Yoshimatsu Y, Nakahara T, Tanaka K, Inagawa Y, Narisawa-Saito M, Yugawa T, et al. Roles of the PDZ-binding motif of HPV 16 E6 protein in oncogenic transformation of human cervical keratinocytes. Cancer Sci 2017; 108: 1303-1309.
16. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999; 18: 7690-7700.
17. Münger K, Scheffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992; 12: 197-217.
18. Lim HY, Han J, Yoon H, Jang KL. Tumor suppressor p53 inhibits hepatitis B virus replication by downregulating HBx via E6AP-mediated proteasomal degradation in human hepatocellular carcinoma cell lines. Viruses 2022; 14:2313-2333.
19. Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer 2021; 1876: 188556-188587.
20. Shimada M, Yamashita A, Saito M, Ichino M, Kinjo T, Mizuki N, et al. The human papillomavirus E6 protein targets apoptosis-inducing factor (AIF) for degradation. Sci Rep 2020; 10: 14195-14208.
21. Pal A, Kundu R. Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy. Front Microbiol 2019; 10: 3116-3130.
22. Khalil MI, Yang C, Vu L, Chadha S, Nabors H, Welbon C, et al. HPV upregulates MARCHF8 ubiquitin ligase and inhibits apoptosis by degrading the death receptors in head and neck cancer. PLoS Pathog 2023; 19: e1011171-1011188.
23. Lechien JR, Descamps G, Seminerio I, Furgiuele S, Dequanter D, Mouawad F, et al. HPV involvement in the tumor microenvironment and immune treatment in head and neck squamous cell carcinomas. Cancers (Basel) 2020; 12: 1060-1084.
24. Abohassan M, Alshahrani M, Alshahrani MY, Rajagopalan P. In silco and in vitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations. Med Oncol 2022; 39: 249.
25. Sousa da Silva AW, Vranken WF. ACPYPE - AnteChamber PYthon Parser interfacE. BMC Res Notes 2012; 5:367-374.
26. Valdés-Tresanco MS, Valdés-Tresanco ME, Valiente PA, Moreno E. gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput 2021; 17: 6281-6291.
27. Kamli H, Zaman GS, Shaikh A, Mobarki AA, Rajagopalan P. A combined chemical, computational, and in vitro approach identifies SBL-105 as Novel DHODH inhibitor in acute myeloid leukemia cells. Oncol Res 2022; 28: 899-911.
28. Tobeigei FH, Gahtani RM, Shaikh A, Al Ali A, Kameli N, Kamli H, et al. Computational high-throughput screening and in vitro approaches identify CB-006-3; A novel PI3K-BRAF(V600E) dual targeted inhibitor against melanoma. Oncol Res 2021; 29: 305-318.
29. Yeo-Teh NSL, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci 2018; 19: 1706-1732.
30. Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature 2016; 529:541-545.
31. Chitsike L, Duerksen-Hughes PJ. PPI modulators of E6 as potential targeted therapeutics for cervical cancer: Progress and challenges in targeting E6. Molecules 2021; 26: 3004-3017.
32. Li L, Dong X, Tang Y, Lao Z, Li X, Lei J, et al. Deciphering the mechanisms of HPV E6 mutations in the destabilization of E6/E6AP/p53 complex. Biophys J 2022; 121:1704-1714.
33. Li S, Hong X, Wei Z, Xie M, Li W, Liu G, et al. Ubiquitination of the HPV oncoprotein E6 Is critical for E6/E6AP-mediated p53 degradation. Front Microbiol 2019; 10: 2483-2493.
34. Talis AL, Huibregtse JM, Howley PM. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 1998;273:6439-6445.
35. Chen J. The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression. Cold Spring Harb Perspect Med 2016; 6: a026104-0261118.
36. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2011; 2: 466-474.
37. Celegato M, Messa L, Bertagnin C, Mercorelli B, Loregian A. Targeted disruption of E6/p53 binding exerts broad activity and synergism with paclitaxel and topotecan against HPV-transformed cancer cells. Cancers (Basel) 2021; 14: 193-208.
38. Fradet-Turcotte A, Archambault J. Recent advances in the search for antiviral agents against human papillomaviruses. Antivir Ther 2007; 12: 431-451.
39. Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull 2019; 9: 205-218.
40. Li M. The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases. Apoptosis 2021; 26: 235-247.
Iranian Journal of Basic Medical Sciences
Volume 27, Issue 11
November 2024
Pages 1389-1396

Files

Share

How to cite

Statistics